{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:22:40Z","timestamp":1785871360679,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ygyno.2025.05.020","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T15:38:54Z","timestamp":1748619534000},"page":"84-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study)"],"prefix":"10.1016","volume":"198","author":[{"given":"Won Kyung","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Jung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meesun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hwa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.05.020_bb0005","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2025.05.020_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/gyno.1999.5387","article-title":"A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study","volume":"73","author":"Sedlis","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2005.10.019","article-title":"A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study","volume":"65","author":"Rotman","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0020","series-title":"Intensity Modulated Radiation Therapy: A Clinical Overview, Bristol","author":"Das","year":"2020"},{"key":"10.1016\/j.ygyno.2025.05.020_bb0025","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2018.33.e67","article-title":"A survey of radiation therapy utilization in Korea from 2010 to 2016: focusing on use of intensity-modulated radiation therapy","volume":"33","author":"Rim","year":"2018","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0030","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1200\/JCO.20.02530","article-title":"Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer (PARCER): a randomized controlled trial","volume":"39","author":"Chopra","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0035","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2017.77.4273","article-title":"Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203","volume":"36","author":"Klopp","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0050","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3857\/roj.2022.00577","article-title":"Journey to hypofractionation in radiotherapy for breast cancer: critical reviews for recent updates","volume":"40","author":"Kim","year":"2022","journal-title":"Radiat. Oncol. J."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0055","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijrobp.2010.11.080","article-title":"Estimation of alpha\/beta for late rectal toxicity based on RTOG 94-06","volume":"81","author":"Tucker","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0362","article-title":"Quality-of-life outcomes and toxic effects among patients with cancers of the uterus treated with stereotactic pelvic adjuvant radiation therapy: the SPARTACUS phase 1\/2 nonrandomized controlled trial","volume":"8","author":"Leung","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jrr\/rraa085","article-title":"A dummy-run evaluation of postoperative hypofractionated intensity-modulated radiation therapy (POHIM-RT) trials for cervical cancer","volume":"62","author":"Cho","year":"2021","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0070","article-title":"Sigmoid colon perforation after postoperative hypofractionated intensity-modulated radiation therapy in a cervical cancer patient","volume":"1","author":"Kim","year":"2018","journal-title":"Cancer Rep. (Hoboken)"},{"key":"10.1016\/j.ygyno.2025.05.020_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2011.03.034","article-title":"Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer","volume":"122","author":"Chen","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0080","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ygyno.2012.11.012","article-title":"Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer","volume":"128","author":"Folkert","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0085","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ijrobp.2010.04.041","article-title":"Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix","volume":"80","author":"Hasselle","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2021.01.003","article-title":"Hypofractionated radiotherapy in the real-world setting: an international ESTRO-GIRO survey","volume":"157","author":"Rodin","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0095","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.3390\/cancers15133526","article-title":"Stereotactic body radiation therapy in gynecologic oligometastases: an effective but underutilized approach","volume":"15","author":"Sherwani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2025.05.020_bb0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00066-023-02104-7","article-title":"Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation","volume":"200","author":"Moll","year":"2024","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13014-021-01976-2","article-title":"Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost","volume":"17","author":"Phuong","year":"2022","journal-title":"Radiation oncology (London, England)"},{"key":"10.1016\/j.ygyno.2025.05.020_bb0110","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ijrobp.2022.04.008","article-title":"Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer","volume":"113","author":"Viani","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2025.05.020_bb0120","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e35","article-title":"Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor","volume":"31","author":"Kim","year":"2020","journal-title":"J. Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:43:59Z","timestamp":1752576239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825008534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":23,"alternative-id":["S0090825825008534"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.05.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}